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The involvement of brain-derived neurotrophic factor (BDNF) in diﬀerent central nervous system (CNS) diseases suggests that this
neurotrophin may represent an interesting and reliable therapeutic target. Accordingly, the search for new compounds, also from
natural sources, able to modulate BDNF has been increasingly explored. The present review considers the literature on the eﬀects of
botanicals on BDNF. Botanicals considered were Bacopa monnieri (L.) Pennell, Coﬀea arabica L., Crocus sativus L., Eleutherococcus
senticosus Maxim., Camellia sinensis (L.) Kuntze (green tea), Ginkgo biloba L., Hypericum perforatum L., Olea europaea L. (olive
oil), Panax ginseng C.A. Meyer, Rhodiola rosea L., Salvia miltiorrhiza Bunge, Vitis vinifera L., Withania somnifera (L.) Dunal,
and Perilla frutescens (L.) Britton. The eﬀect of the active principles responsible for the eﬃcacy of the extracts is reviewed and
discussed as well. The high number of articles published (more than one hundred manuscripts for 14 botanicals) supports the
growing interest in the use of natural products as BDNF modulators. The studies reported strengthen the hypothesis that
botanicals may be considered useful modulators of BDNF in CNS diseases, without high side eﬀects. Further clinical studies are
mandatory to conﬁrm botanicals as preventive agents or as useful adjuvant to the pharmacological treatment.
1. Introduction
One of the most complete forms of plasticity was described
by Donald Hebb in 1949 who proposed an explanation for
the adaptation of neurons during cognition andmemory; this
theorywas later summarized by the famous sentence “neurons
that ﬁre together, wire together” [1]. Brieﬂy, neuronal plastic-
ity describes the versatility of neuronal connectivity and
circuitry to which the nervous system responds and adapts
to changing conditions of the body and the environment.
Among the genes involved in the modulation of neuronal
activity, neurotrophic factors (NTFs), in particular the neu-
rotrophin family of signaling proteins, play an important role
in brain development [2, 3] and in adulthood modulating
axonal and dendritic growth and remodeling, membrane
receptor traﬃcking, neurotransmitter release, and synapse
formation and function [4].
Brain-derived neurotrophic factor (BDNF) as well as
nerve growth factor (NGF) is the most studied and best-
characterized neurotrophins of the central nervous system
(CNS), where they are involved in the development and
maintenance of physiological brain functions. The features
of the BDNF system have been extensively reviewed else-
where [5, 6]. Brieﬂy, in rodents, the BDNF gene consists of
nine 5′ untranslated exons, each linked to individual pro-
moter regions, and a 3′ coding exon (IX), which codes for
the BDNF preprotein amino acid sequence [7]. Similarly,
the human Bdnf gene is also transcribed through multiple 5′
exons spliced to a single coding exon [8]. The neurotrophin
transcription is ﬁnely regulated by several intracellular signal-
ing pathways and by diﬀerent transcription factors [8–11].
Moreover, BDNF function is also highly dependent on
translation and posttranslational changes. Indeed, BDNF is
initially synthesized as a precursor form (proBDNF, 32 kDa)
that can be cleaved into the mature neurotrophin (mBDNF,
14 kDa) or transported to the plasma membrane and released
in an unprocessed manner. Upon release, the two forms of
BDNF protein, as all the neurotrophins, bind with diﬀerent
receptors with multiple and opposite biological functions.
The proBDNF binds with high-aﬃnity p75NTR leading to
apoptosis, neurite retraction, and synaptic weakening and
facilitating long-term depression, whereas mBDNF binds
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with TrkB receptors promoting cell survival, neurite exten-
sion, synaptic strengthening, and long-term potentiation
(LTP) [4, 12, 13].
Alterations of NTF expression, including BDNF, are
involved in the development of a variety of CNS diseases,
including neurodegenerative disorders (Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, and amyotrophic
lateral sclerosis) as well as psychiatric disorders (depression
and schizophrenia) [14–16]. NTFs may be considered thera-
peutic targets, but their use has been limited so far by several,
still unresolved, methodological problems aimed to guaran-
tee their safety and eﬃcacy [14, 15]. In particular, results
from clinical studies using BDNF as a therapeutic agent have
not been encouraging, possibly due to a failure of attaining
relevant concentration of the trophic molecule at receptors.
The two main problems seem to be related to the inability
to deliver BDNF across the blood–brain barrier (BBB) and
to the poor bioavailability of BDNF owing to its physiochem-
ical properties [17].
For this reason, alternative options may be devoted to
increase the endogenous content of BDNF. Accordingly, sev-
eral drugs increase, indirectly, BDNF levels; however, consid-
ering the high number of nonresponder patients and the
presence of serious side eﬀects, the search for new strategies
able to interfere with the mechanisms underlying CNS dis-
eases would greatly beneﬁt a high number of subjects. Botan-
icals are widely consumed all over the world as diﬀerent
types of products, including herbal medicinal products, plant
food supplements, and functional foods. Nowadays, they are
commonly used for promoting health and treating or pre-
venting a variety of diseases even if, in most cases, clear evi-
dence about their clinical eﬃcacy is lacking. Emerging
research provides substantial evidence to classify botanicals
as modulators of markers, which are signiﬁcantly altered
during CNS dysfunction.
Some natural products are classiﬁed as antidepressants or
anxiolytics according to the legislation of the countries in
which they are sold [18, 19]. The ability of a variety of botan-
icals to positively modulate mood disorders and cognitive
impairment resides on understanding that most of them are
eﬃciently absorbed in humans. Recently, biologically active
metabolites of botanicals able to interact with multiple tar-
gets associated with the promotion of resilience against mood
disorders and cognitive impairment in response to stress
have been discovered. Interventions with botanicals may
beneﬁt anxiety disorders by diﬀerent mechanisms which
include eﬀects on the GABA system either via inducing ion
channel transmission or through alteration of membrane
structures [20]. A consistent number of botanicals, including
Ginkgo biloba L., clinically improve cognitive impairment by
ameliorating microvascular function in the brain whereas
Bacopa monnieri (L.) Pennell has provided indications as a
memory enhancer and protective agent in epilepsy [21].
The aim of the present review is to summarize the rele-
vant literature concerning the role of botanicals as modula-
tors of BDNF (Figure 1). Electronic literature searches were
conducted in December 2016 taking into consideration also
Epub articles and using Web of Science and PubMed data-
bases. Search limit was the English language whereas no limit
was applied for the year of publication. Research articles were
searched for title and abstract using the following search
terms: Latin name or common name or vernacular name of
the plant matched with BDNF. Studies in the literature were
found for the following botanicals: Bacopa monnieri (L.) Pen-
nell, Coﬀea arabica L., Crocus sativus L., Eleutherococcus sen-
ticosus Maxim., Camellia sinensis (L.) Kuntze (green tea),
Ginkgo biloba L., Hypericum perforatum L., Olea europaea
L. (olive oil), Panax ginseng C.A. Meyer, Rhodiola rosea L.,
Salvia miltiorrhiza Bunge, Vitis vinifera L., Withania somni-
fera (L.) Dunal, and Perilla frutescens (L.) Britton.
This review emphasizes the part of the plant used, stan-
dardization of the active principles, and the protocol to man-
age studies in addition to the description of the behavioral
test employed (Table 1). The eﬀect of the pure compounds
occurring in some plant able to modulate BDNF, such as sal-
idroside, caﬀeine, epigallocatechin-3-O-gallate, and ginseno-
sides Rg1 and Rb1, will be reviewed as well whereas the eﬀect
of the pure compounds curcumin and resveratrol, which
have been extensively studied as eﬀective modulators of
BDNF, will not be considered in the present review. In addi-
tion to the eﬀect of the selected botanicals and/or their active
compounds, papers describing biological eﬀects of their asso-
ciation will be also considered.
2. Bacopa monnieri (L.) Pennell
Bacopa monnieri (L.) Pennell is a member of Scrophularia-
ceae traditionally used in Ayurvedic medicine for epilepsy
and asthma. The best-characterized compounds occurring
in the whole plant are dammarane-type triterpenoid sapo-
nins known as bacosides (mostly bacoside A), which are con-
sidered the main responsible for the biological activity [22].
2.1. In Vitro Studies. Two studies investigated the protective
eﬀect of Bacopa monnieri extract (BME) in vitro. In PC12
cells, pretreatment with a hydroalcoholic extract completely
prevented the reduction of BDNF mRNA levels associated
with cellular damage induced by scopolamine [23] or sodium
nitroprusside [24].
2.2. In Vivo Studies. The eﬀect of Bacopa monnieri was inves-
tigated, at preclinical levels, in eight studies using diﬀerent
animal models.
The unpredictable chronic mild stress (CMS), a well-
established animal model of depression, was used to assess
the ability of a compound to exert an antidepressant-like
eﬀect. Administration of BME by gavage (80 or 120mg/kg)
prevented the behavioral deﬁcits and the reduction of 3′
UTR-long BDNF gene expression [25], as well as of the pro-
tein levels of the mature form in the hippocampus and fron-
tal cortex of chronically stressed rats [26]. Similar eﬀects were
observed after treatment with the tricyclic antidepressant
drug imipramine [25–27].
The cognition-enhancing properties of Bacopa monnieri
were investigated in the scopolamine rodent model of “cho-
linergic amnesia” and in the olfactory bulbectomy (OBX), a
model of cognitive and emotional dysfunction typical of neu-
rodegenerative pathologies such as Alzheimer’s disease [28].
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Interestingly, chronic treatment (62 days) with an alco-
holic BME (50mg/kg in the drinking water) ameliorated
the memory disturbance and completely normalized the
reduction of hippocampal BDNF mRNA levels due to the
OBX [29].
Moreover, 1 week of oral (os) treatment with the hydro-
alcoholic BME (10, 20, and 40mg/kg) dose-dependently pre-
vented the memory deﬁcits induced by scopolamine and
normalized the reduction of BDNF mRNA levels in the rat
hippocampus [30]. A similar eﬀect was found in young mice
at postnatal day (PND) 30 [31] treated with CDRI-08 (BME
standardized in bacoside A) (3mg/kg, i.p., 7 days) before and
after scopolamine injection. Both the protocols attenuated
the decrease in proBDNF protein levels in the mouse cere-
brum, caused by scopolamine administration. Furthermore,
CDRI-08 per se induced an increase in BDNF gene and pro-
tein expression [31].
In a recent study, administration of CDRI-08 (80mg/kg,
i.p., 2 weeks) signiﬁcantly increased the mRNA and the pro-
tein levels of proBDNF in the hippocampus of young rats
(PND 32). Interestingly, this eﬀect paralleled the upregula-
tion of the unmethylated CpG islands 1 and improved the
object recognition memory [32]. Using the same regime of
treatment, CDRI-08 facilitated memory acquisition in the
fear-conditioning paradigm and increased the expression
of BDNF exon IV transcript in the hippocampus of PND
30 rats [33].
On this basis, even if clinical studies are needed, preclin-
ical results indicate that Bacopa monnieri extract administra-
tion modulates a BDNF eﬀect that may underline its ability as
an antidepressant and procognitive agent.
3. Coffea arabica L.
The coﬀee plant, a woody perennial tree growing at higher
altitudes, belongs to the family of Rubiaceae. Although beans
are particularly rich in caﬀeine, other constituents are present
in a considerable amount, including tocopherols and caﬀeic
acid derivatives, such as chlorogenic acid.
In the literature are present studies reporting the eﬀect of
caﬀeine on BDNF, whereas the eﬀect of a Coﬀea arabica
extract from fruits was investigated only in one clinical study.
3.1. In Vitro Studies. Three studies investigated the in vitro
eﬀect of caﬀeine on BDNF. In particular, caﬀeine upregulated
the BDNF protein levels in mouse hippocampal slices
(100μM for 5 minutes) [34], increased the BDNF release in
hippocampal neurons [35], and eﬃciently stimulated the
BDNF isoform I and IV expression in the presence of KCl
(10mM) in cortical neurons [36].
3.2. In Vivo Studies. 15 studies investigated the eﬀect of caf-
feine on BDNF in vivo. Treatment of zebraﬁsh embryos with
caﬀeine (100μM) increased the BDNF mRNA levels speciﬁ-
cally after 48 and 72 hours postfertilization [37].
Caﬀeine administration in naïve rats, during adulthood,
counteracted the negative eﬀect exerted by its intake in early
life by increasing the protein levels of mBDNF [38]. Diﬀer-
ently, administration of caﬀeine (1.0 g/L in drinking water)
two weeks before mating, during pregnancy, and up to
embryonic days 18–20 (E18 or E20) caused a decrease in
BDNF protein levels in the whole cortex until E18, while an
increase was found at E20 [39].
Caﬀeine intake during adolescence (from PND 28 to
PND 53) by drinking water decreased both proBDNF and
mBDNF in the hippocampus at 1.0mg/mL, while an increase
was found in the cerebral cortex at 0.3 and 1.0mg/mL [40].
Interestingly, caﬀeine at 0.1 or 0.3mg/mL improved recogni-
tion memory while the highest dose impaired the nonasso-
ciative memory [40].
During adulthood to old age, 30 consecutive days of free
access to drinking water containing 1mg/mL of caﬀeine solu-
tion reduced age-related memory impairment and increased
proBDNF in the hippocampus of young adult (3 months old)
5′ AAAAAAAAAAAn 3′
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Figure 1: Eﬀects of botanicals on BDNF mRNA and protein levels. The ﬁgure shows botanicals acting at transcriptional and translational
levels.
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and middle-aged rats (12 months old); the treatment also
prevented the age-related increase in the mature form in
older rats [41].
Accordingly, prolonged treatment (12 months) with
caﬀeine solution (1mg/mL in drinking water) in 6-month-
old mice counteracted the increase in mBDNF in the hippo-
campus of aged animals and prevented the age-associated
memory decline [42]. Moreover, 4 consecutive days of caf-
feine treatment (10mg/kg, i.p.) increased the protein levels
of mBDNF in the same brain region and improved the per-
formance in the object recognition task in adult mice [43].
In the hippocampus of a mouse model of Alzheimer’s
disease, induced by AlCl3, cotreatment with caﬀeine
(1.5mg/day by gavage) partially prevented the decrease in
BDNF gene expression, while the pretreatment completely
normalized the impairment [44]. Accordingly, chronic
caﬀeine treatment (0.75mg/day or 1.5mg/day for 8 weeks)
dose-dependently increased the mBDNF protein levels in
the hippocampus ofAPP/PS1 (Aβprecursor protein/presene-
lin-1) double transgenic mice, another model of Alzheimer’s
disease, and reversed the memory impairment observed in
the Morris water maze (MWM) test [45].
Chronic caﬀeine treatment (0.33mg/L in drinking water)
during 4 weeks of psychological stress (intruder model)
restored the reduced BDNF protein levels found in the
stressed group [46]. The i.p. injection of caﬀeine once a week
was enough to normalize the deﬁcit of BDNF protein levels
induced by a high-fat diet. At behavioral level, caﬀeine fully
prevented the diet-induced impairment and restored the spa-
tial memory observed in control animals. Neither diet nor
caﬀeine treatment aﬀected motor activity [47].
Since sleep is a critical factor in memory consolidation
and neural plasticity [48], the eﬀect of the chronic caﬀeine
treatment on sleep loss was investigated. Oral administration
of caﬀeine (60mg/kg) or the psychostimulant modaﬁnil
(100mg/kg), at the onset of the light phase during 48 hours
of sleep deprivation (SD), restored the normal levels of cell
proliferation improving BDNF expression in the dentate
gyrus [49]. Accordingly, 4 weeks of caﬀeine treatment in
drinking water (0.3 g/L) prevented the SD-induced decrease
in neurotrophin levels in the dentate gyrus and in the cornu
ammonis-1 (CA1) of the hippocampus [50, 51] and allevi-
ated the impairment in the spatial long-term memory
observed in sleep-deprived rats, also through the modulation
of BDNF protein levels [52].
In summary, caﬀeine aﬀects BDNF protein levels with a
speciﬁc temporal and dose proﬁle in normal animals. While
administration during adulthood or old age increased BDNF,
caﬀeine intake at high doses in early life downregulated the
neurotrophin concentration.
Moreover, even if few studies investigated the eﬃcacy of
caﬀeine in animal models of pathology, they provide promis-
ing results.
At behavioral levels, caﬀeine was evaluated as a cognitive
enhancer with positive eﬀects.
3.3. Clinical Studies. The clinical study by Reyes-Izquierdo
et al. [53] investigated the eﬀect of three diﬀerent coﬀee fruit
extracts (100mg dose per os) on BDNF plasma levels in
healthy subjects. Coﬀee fruit concentrate powder (WCFC)
(0.7% caﬀeine) but neither green coﬀee caﬀeine (N677)
(72.8% caﬀeine) nor green coﬀee bean extract (N625) (2%
caﬀeine) increased the level of BDNF in blood suggesting that
the eﬀect of WFCF might be related to the amount of procya-
nidins rather than to caﬀeine [53].
4. Crocus sativus L.
Crocus sativus L. belongs to the Iridaceae family; stigmas are
commonly known as saﬀron and are widely cultivated in Iran
and used in modern and traditional medicines. The color of
saﬀron is mostly due to the carotenoid named crocin, which
is considered among the active principles mostly responsible
for neuroprotective activity [54].
4.1. In Vivo Studies. Two in vivo studies investigated the eﬀect
of Crocus sativus on BDNF expression. Crocin administra-
tion (12.5mg/kg, i.p.) for 21 days to naïve male Wistar rats
exerted an antidepressant eﬀect and signiﬁcantly increased
the transcription levels of BDNF in the hippocampus [55].
Similarly, chronic treatment with C. sativus aqueous extract
(40, 80, or 160mg/kg/day, i.p.), enhanced the gene and pro-
tein levels of BDNF in the rat hippocampus. Moreover, at
40 and 160mg/kg/day, an antidepressant activity was also
observed. Similar results were obtained following imipra-
mine injection (10mg/kg) [56].
5. Eleutherococcus senticosus (Rupr. &Maxim.)
Maxim.
Eleutherococcus senticosus Maxim. or Acanthopanax sentico-
sus Harms, also called “Siberian ginseng,” is a small shrub
from the Araliaceae family. Eleutherococcus consists of the
whole or cut dried roots of the plant containing lignans, phe-
nylpropanoids, and dicaﬀeoylquinic acids [57].
5.1. In Vitro Studies. One paper investigated in vitro the
eﬀect of Eleutherococcus senticosus on BDNF. A commercial
dry aqueous extract of Acanthopanax senticosus stem bark
(ASE) normalized the reduction of BDNF mRNA levels
produced by the administration of corticosterone (200μM)
for 24 h in PC12 cells. Diﬀerent concentrations of ASE
(100, 200, and 400μg/mL) signiﬁcantly increased the
mRNA expression of the neurotrophin in a concentration-
dependent fashion [58].
Unfortunately, no in vivo or clinical studies are reported
in the literature on the modulation of BDNF by E. senticosus,
and no clear-cut conclusions can be drawn.
6. Ginkgo biloba L.
Ginkgo biloba is an ancient Chinese tree belonging to the
family of Ginkgoaceae, cultivated for its health-promoting
properties. Although both leaves and seeds are currently used
as herbal medicine in China, in many countries, leaves are
considered the unique source of active principles and dried
green leaves are used for supplying pharmaceutical formula-
tions or extracts as ingredients of food supplements. Ginkgo
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biloba and its constituents were evaluated on BDNF in three
in vitro, eight in vivo, and one clinical studies.
6.1. In Vitro Studies. Ginkgo biloba leaf extract (EGb761,
100μg/mL) restored the levels of BDNF protein (both pro
and mature form) in cells stimulated with appropriate
medium able to induce amyloid β-peptide Aβ expression.
Administration of individual EGb761 constituents, namely,
ginkgolides A (GA), B (GB), C (GC), and J (GJ) and 10μg/
mL bilobalide, increased the levels of BDNF by following a
similar pattern [59].
Accordingly, ﬂavonol-enriched extract containing quer-
cetin, kaempferol, and isorhamnetin (50μg/mL) signiﬁcantly
restored BDNF protein expression in double transgenic APP/
PS1 primary neurons [60].
Moreover, 100μg/mL of YY162, a patented formula con-
sisting of terpenoid-strengthenedGinkgo biloba and ginseno-
side Rg3, prevented the reduction of BDNF protein levels
induced by 48 h of Aroclor 1254 in SH-SY5Y neuroblastoma
cell line [61].
6.2. In Vivo Studies. Ginkgo ﬂavonols (50mg/kg, per os, daily
for 4 months) signiﬁcantly normalized the deﬁcit of BDNF
protein levels in the hippocampus of transgenic APP/PS1
mice and improved spatial learning similar to the adminis-
tration of the antidepressant SSRI (serotonin selective reup-
take inhibitor) ﬂuoxetine (10mg/kg), while exerting an
antidepressant eﬀect on wild-type animals [60].
YY162 (200mg/kg, per os, from PND 21 to PND 35)
signiﬁcantly attenuated the reduction of BDNF protein in
the prefrontal cortex and ameliorated the ADHD- (attention
deﬁcit hyperactivity disorder-) like behavioral phenotype
induced by Aroclor 1254 [61].
Intravenous (i.v.) injections of EGb761 (45mg/kg), just
before ischemia-reperfusion, induced a signiﬁcant increase
in BDNF positive neurons in the hippocampus with respect
to the control group; the treatment signiﬁcantly reduced the
behavior grade measured by a postural reﬂex test at 24 h
after reperfusion. The eﬀect exerted by EGb761 was compa-
rable to that exerted by the antihypertensive nimodipine
(2mg/kg) [62].
Chronic treatment with EGb761 (100mg/kg/day via oral
gavage for 30 days) increased the BDNF levels in plasma of
both young and aged (18 months) rats, but the eﬀect was
not statistically signiﬁcant; on the opposite, in the aged
female group, treatment signiﬁcantly increased the number
of platform crossings in the aged female group in the open
ﬁeld test (OFT) [63].
Pretreatment with EGb761 (100 or 150mg/kg/day, per os
for 10 days) signiﬁcantly inhibited the reduction of hippo-
campal BDNF protein due to LPS (lipopolysaccharide) injec-
tions (0.83mg/kg, i.p.) and showed an antidepressant eﬀect
[64]. Furthermore, EGb761 treatment (50mg/kg/day, by oral
gavage for 5 weeks) normalized the reduction of BDNF pro-
tein levels induced by the ﬁrst-generation antipsychotic halo-
peridol injection (2mg/kg/day, i.p., 5 weeks) in the prefrontal
cortex, striatum, substantia nigra, and globus pallidus and
reduced the vacuous chewing movement scores over the
withdrawal period [65]. Finally, 28 days of treatment with
EGb761 (40mg/kg) increased the expression of BDNF and
explored the behavior in stressed rats. The eﬀect was com-
parable to that of the SNRI (serotonin noradrenaline reup-
take inhibitor) antidepressant venlafaxine (15mg/kg) [66].
Administration of bilobalide (10mg/kg, i.p.) for 10 days
enhanced the hippocampal protein levels in normal mice
more eﬃciently than that of ﬂuoxetine (10mg/kg) [67].
Taken together, these preclinical results suggest that
Ginkgo biloba L. administration may be eﬃcacious in restor-
ing BDNF in pathologies characterized by neurotrophin
deﬁcits. The main problem is that studies take into consider-
ation diﬀerent animal models mimicking diﬀerent kinds of
diseases, from Alzheimer’s disease to stroke, thus making
further results mandatory to conﬁrm the supposed eﬀect
on BDNF.
6.3. Clinical Studies. In the unique clinical study, one hun-
dred ﬁfty-seven patients aﬀected by tardive dyskinesia (TD)
associated with long-term neuroleptic treatment were ran-
domized to either EGb761 80mg three times a day or placebo
treatment. EGb761 signiﬁcantly increased the BDNF protein
plasma levels compared with placebo at week 12 in TD
patients [68].
7. Green Tea (Camellia sinensis (L.) Kuntze)
Tea obtained from the dried leaves of Camellia sinensis (L.)
Kuntze (Theaceae) is one of the most widely consumed bev-
erages in the world. Green tea (GT) contains many bioactive
compounds including amino acids (i.e., L-theanine), ﬂavo-
noids (i.e., catechins), and their derivatives, which may con-
stitute up to 30% of the dried weight [69].
7.1. In Vitro Studies. The potential neuroprotective eﬀect of
some constituents of green tea leaves, including catechins,
was investigated in two in vitro studies.
L-Theanine pretreatment (500μM) exerted a protective
eﬀect by signiﬁcantly attenuating the downregulation of
BDNF protein due to the treatment with two disease-
related neurotoxicants (rotenone and dieldrin) in the human
cell line SH-SY5Y [70].
Moreover, pretreatment with GT catechins, such as epi-
catechin (EC) and (+)-catechin, prevented the reduction
of mBDNF and the increase in the precursor form induced
by the toxic HIV (human immunodeﬁciency virus) protein
Tat [71].
7.2. In Vivo Studies. 10 papers investigated the eﬀects of GT
on BDNF. Chronic administration of L-theanine at diﬀerent
doses (0.2, 0.4, and 10mg/kg, i.p.) exerted an antidepressant
activity and upregulated the protein levels of BDNF in the
hippocampus, but not in the cortex of adult mice [72]. More-
over, daily consumption of the ﬂavonol (−)-EC (4mg/day in
water for 14 weeks, ad libitum) in adult mice led to an
anxiolytic-like eﬀect and increased the pro and mBDNF
levels in the hippocampus, while no eﬀect was found in the
cortex [73].
The eﬀect of theanine administration during develop-
ment was evaluated on rat pups receiving 0.3% theanine
(through lactation before weaning and then directly by
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drinking water) showing increased exploratory activity and
enhanced object recognition memory and levels of mBDNF
protein in the hippocampus [74].
Assuncao et al. demonstrated that the decrease in BDNF
protein levels in the rat hippocampus, associated with aging,
was prevented by drinking GT-infused drink as the only
drink available from 12 to 19 months of age [75]. Similarly,
catechins (0.05% and 0.1%) mixed with drinking water for
6 months improved age-related spatial learning and memory
decline of 14-month-old female mice and upregulated the
hippocampal mature form of BDNF to levels comparable to
those observed in young animals [76].
On the contrary, the addition of epigallocatechin-3-O-
gallate (EGCG) (182mg/kg/day) and β-alanine (417mg/kg/
day) to the diet for 4 months did not improve memory and
did not alter the mRNA expression of BDNF in the hippo-
campus of 19-month-old male mice [77].
The GT eﬀect has been studied in diﬀerent animal
models of learning impairments. Administration (1 g in
100mL water for 5min at 100°C, corresponding to 0.6–
1mg EGCG per day), from gestation to adulthood, cor-
rected the lower BDNF mRNA levels in the hippocampus
of mice overexpressing DYRK1A (dual-speciﬁcity tyrosine
phosphorylation-regulated kinase 1A) but did not aﬀect
the performance in memory tasks [78].
In senescence-accelerated mice-prone 8 (SAMP8), a
model characterized by the early onset of learning and mem-
ory deﬁcits along with overproduction of soluble amyloid
peptide in the brain, the chronic treatment with green tea cat-
echins (GTC) (0.05% and 0.1% in drinking water for 6
months) restored the reduction of mBDNF levels in the hip-
pocampus and prevented the learning impairment of SAMP8
mice [79]. Finally, 4 months of EC administration (50mg/kg
daily in drinking water) normalized the low levels of BDNF
protein in the hippocampus of 8-month-old APP/PS1 mice,
without aﬀecting escape latency in MWM [80].
Teasaponin (10mg/kg, i.p. for 21 days) rescued the
upregulation of BDNF induced by the adipocyte-secreted
hormone leptin in the prefrontal cortex of high-fat diet-fed
mice. In addition, teasaponin (20 or 40μM) reversed the
eﬀect of palmitic acid on the alteration induced by leptin in
cultured cortical neurons [81].
To summarize, these studies provide robust evidence
regarding the role of green tea as a modulator of BDNF and
in improving cognitive performance at preclinical levels.
8. Hypericum perforatum L.
Hypericum perforatum L. (HYP), known as St John’s wort, is
a plant belonging to the family of Hypericaceae. Flowering
aerial parts are used in many countries for their antidepres-
sant activity, mostly ascribed to the active principles hyper-
forin, hypericin, and pseudohypericin [18, 57].
8.1. In Vivo Studies. The antidepressant activity ofHypericum
perforatum was investigated at preclinical level in two in vivo
studies using the CMS animal model. The chronic treatment
with hydroalcoholic extract of HYP (350mg/kg per os, 21
days) normalized the reduction of mRNA expression of
BDNF found in the hippocampus of stressed mice [82]. On
the contrary, Butterweck et al. showed that the chronic
administration of HYP methanolic extract (500mg/kg, per
os) did not prevent the stress-induced decrease in BDNF
mRNA levels in the rat hippocampus, produced by the
immobilization stress protocol (2 h once a day for 7 days)
[83]. The diﬀerent outcomes between these two preclinical
studies could be due to the type of stressors or the protocol
of treatment used.
8.2. Clinical Studies. In one large cohort of subjects, chronic
HYP treatment restored the normal protein concentration
of BDNF in the serum of depressed patients. This normaliza-
tion was limited to HYP and serotonin reuptake inhibitors,
whereas other classes of antidepressants, including the tricy-
clics and the noradrenergic and speciﬁc serotoninergic anti-
depressant, were ineﬀective. The limitation of this study is
that the dose of the diﬀerent drugs used is not clearly indi-
cated [84].
9. Olive Oil (Olea europaea L.)
Olive oil is the main source of fat in the Mediterranean-style
diet. Health beneﬁt of olive oil consumption has been in part
ascribed to minor phenol components (i.e., oleuropein, lig-
stroside aglycones, and hydroxytyrosol (HT)) whose compo-
sition varies qualitatively and quantitatively depending on
the stage of fruit ripeness or the region of cultivation [85, 86].
9.1. In Vivo Studies. Five animal studies were performed to
test the eﬀect of olive oil components on BDNF. The admin-
istration of a mixture of olive oil polyphenols extracted from
the olive residues (pomace) (10mg/kg, i.p., 10 days) signiﬁ-
cantly increased the BDNF protein levels in the hippocampus
and in the olfactory lobes, while decreasing the neurotrophin
in the frontal cortex [87]. Moreover, this regime of treatment
did not aﬀect pain sensitivity in the hot-plate test or stress
response in the FST in naïve animals [87].
Diﬀerently, if the blend of polyphenols was extracted
from olive leaves (20mg/kg, i.p. for 15 days), BDNF protein
levels were downregulated in the hippocampus and striatum
and upregulated in the olfactory lobes. Polyphenol adminis-
tration signiﬁcantly increased the concentration of BDNF
protein in themouse serum [88]. Interestingly, a diet enriched
in olive oil components during prenatal life until weaning
induced, at adulthood, an upregulation of the mRNA levels
of the total BDNF and of the isoforms IV and VI in the pre-
frontal cortex but not in the hippocampus [89].
Before mating, the treatment with HT (10 or 50mg/kg/
day by gavage for 2 weeks), one of the most bioactive pheno-
lic compound in olive oil, prevented the signiﬁcant decrease
in proBDNF and mBDNF due to prenatal stress exposure
in male oﬀspring and improved cognitive functions [90].
In Alzheimer’s disease mouse model, HT chronic treat-
ment (10mg/day by gavage for 14 days) attenuated the
spatio-cognitive deﬁcits and normalized the hippocampal
BDNF mRNA levels [91].
9.2. Clinical Studies. The eﬀect of olive oil was investigated in
two clinical studies. TakingMediterranean diet supplemented
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with olive oil for 3 years did not alter the plasma BDNF pro-
tein levels in normal subjects [92]. Moreover, the administra-
tion of a blend of olive polyphenols (a tablet containing a
total of 50mg/day) extracted from the olive pomace and con-
taining mostly HT and oleuropein for 15 consecutive days in
alcoholic patients undergoing withdrawal induced a transient
decrease in mBDNF protein levels in the serum after 3 days
of treatment [93].
Even if not so many, in vivo studies provide positive
results, while the eﬀect in clinical studies (only 2) appears
inconsistent or negligible.
10. Panax ginseng C.A. Meyer
Ginseng radix consists of the whole or cut dried root of
Panax ginseng C.A. Meyer and contains not less than 0.4%
of the sum of ginsenosides Rg1 (Rg1) and Rb1 (Rb1). Ginse-
nosides are triterpenoid saponins which are the main respon-
sible for the biological activities of ginseng extracts [57].
10.1. In Vitro Studies. Five studies were performed in vitro to
test the eﬀect of ginseng or ginsenosides on BDNF. Rg1 treat-
ment upregulated the mRNA expression and protein secre-
tion of BDNF in primary cultured olfactory cells (Rg1,
40μg/mL for 72 h) [94] and in Schwann cells (Rg1, 50μM
for 24 h) challenged with 0.2% H2O2 for 4 h [95]. The beneﬁ-
cial eﬀect was also found in diﬀerent “pathological condi-
tions.” Indeed, pretreatment of rat brain slices with Rg1 at
diﬀerent concentrations (60, 120, and 240μM for 2 h), before
okadaic acid administration, increased the BDNF protein
expression in a dose-dependent fashion [96].
Red ginseng extract (RGE) (0.01–1.0mg/mL applied for
1 h) dose-dependently increased the BDNF protein expres-
sion in primary cultures of rat hippocampal neurons exposed
for 48 h to 100μMkainic acid [97]. BDNF protein levels were
signiﬁcantly increased in PC12 cells subjected to oxygen glu-
cose deprivation/reperfusion (OGD/R) for 4 h by ginsenoside
Rd (Rd) at 50 and 100μM [98].
10.2. In Vivo Studies. A total number of 25 studies were per-
formed in vivo, mostly on pure ginsenosides.
Deﬁcits induced at protein levels by the exposure to CMS
were normalized by concomitant treatment with ginseng
standardized in the saponin content (GTS) (50 and 100mg/
kg) [99] or Rg1 (2.5, 5, 10, and 20mg/kg, i.p.) [100] in the
hippocampus and with ginsenoside Rb3 (Rb3) (30, 75, and
150mg/kg, intragastrically) both in the prefrontal cortex
and in the hippocampus [101]. At 40mg/kg (i.p.), the eﬀect,
for Rg1, was also found in the lateral amygdala [102, 103].
Rg1 corrected the alteration found at translational level
[100] similar to ﬂuoxetine (10mg/kg) [104, 105] and imipra-
mine [100]. Moreover, all the compounds reverted the
behavioral phenotype associated with this model [99–103].
A comparable eﬀect was found after chronic restraint
stress with Re (50mg/kg) and ﬂuoxetine (10mg/kg) at tran-
scriptional level in the hippocampus [106], while Rg1
(10mg/kg) prevented the reduction of mBDNF in the pre-
frontal cortex [107]. Re produced an antidepressant and
anxiolytic eﬀect [106], whereas Rg1 improved learning and
memory [107].
The decreased expression of BDNF mRNA, found after
the single prolonged stress, was signiﬁcantly restored to nor-
mal level by chronic treatment with Rb1 (10 or 30mg/kg, i.p.,
14 days) or ﬂuoxetine (10mg/kg). Rb1 at 30mg/kg normal-
ized the percentage of time spent in the open arms in the ele-
vated plus maze [104]. Rb1 (10mg/kg), administered 30min
before acute immobilization stress, signiﬁcantly inhibited the
stress-mediated decline in BDNF mRNA level [108].
Accordingly, GTS (25 or 50mg/kg/day), similar to ﬂu-
oxetine (10mg/kg), signiﬁcantly upregulated the mRNA
and protein levels of BDNF in the hippocampus of
corticosterone-treated mice (20mg/kg, once a day for 22
days) but not in that of normal animals and produced
an antidepressant eﬀect [105].
Panax ginseng extract or pure compounds exerted a
positive eﬀect also on the scopolamine animal model. Indeed,
wild ginseng (WG) roots (200mg/kg, i.p.) normalized the
mRNA level of BDNF in the rat hippocampus of the
scopolamine-treated group, as well as reducing the escape
latency in the MWM test [109]. Accordingly, pretreatment
with ginsenosides Rg5 (Rg5) and Rh3 (Rh3) (5, 10, and
20mg/kg, per os) inhibited the reduction of mBDNF protein
expression induced by scopolamine injection (1mg/kg, i.p.)
and reduced the latency time in MWM. The protective eﬀect
of Rh3 (5 and 10mg/kg) on memory deﬁcit was more potent
than that of Rh5 and comparable with that of the acetyl cho-
linesterase inhibitor donepezil (5mg/kg) used in the treat-
ment of Alzheimer’s disease [110].
Oral administration of Rg5 (5, 10, and 20mg/kg) or
donepezil (3mg/kg) prevented the reduction of mBDNF
induced by streptozotocin (STZ) (3mg/kg intracerebroven-
tricular administration) and enhanced the memory reten-
tion, the mean latency time, and the path length with
respect to the STZ group in the MWM test [111].
Rd (10, 20, 40, and 80mg/kg/day, i.p.) prevented the
reduction of BDNF expression in both the cerebral cortex
and lumbar spinal cord in an animal model of encephalomy-
elitis [112].
Rg1 (2.5, 5.0, and 10mg/kg, i.p.) signiﬁcantly increased,
in a dose-dependent manner, the mBDNF protein level in
SAMP8 mice and ameliorated the cognitive impairments
observed in 9-month-old mice [113].
Similarly, chronic treatment with Rg1 (1mg/kg or 10mg/
kg, i.p. for 30 days) signiﬁcantly enhanced the mBDNF
expression in the hippocampal homogenate of middle-aged
rats. Also, proBDNF was upregulated, but the eﬀect was sig-
niﬁcant only for the 10mg/kg-treated group. Furthermore,
Rg1 administration signiﬁcantly improved the memory in
the fear-conditioning task [114].
The protective eﬀect of Rg1 on memory performance and
synaptic plasticity was assessed in a transgenic AD model
constructed by overexpressing APP and PS1. The injection
of 10mg/kg Rg1 for 30 days (i.p.) upregulated the BDNF pro-
tein levels and ameliorated the memory in mice [115].
Moreover, in adult male rats, Rb1 infusion (40mg/kg)
signiﬁcantly increased the BDNF protein expression from
3h to 10 days after middle cerebral artery reperfusion, with
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a peak at 3 days [116]. On the opposite, treatment with Rb1
(7.5mg/mL) by intragastric administration for three days,
three times a day (12.5mL/kg weight) before transient mid-
dle cerebral artery occlusion, did not prevent the increased
levels of BDNF due to the damage. Indeed, BDNF protein
levels were higher in the Rb1 group compared to the
untreated animals [117].
Five- to 7-week-old male C57BL/6J mice were treated
with Rd (10 or 30mg/kg, i.p. for 21 days) ﬁfteen days after
bilateral carotid artery stenosis that induced chronic cerebral
hypoperfusion (CCH). The dramatic decrease in BDNF pro-
tein and mRNA levels observed in the CCH model was
reversed by Rd administration that also improved the mem-
ory task performance [118].
YY162 signiﬁcantly reduced the BDNF protein decline in
the prefrontal cortex and improved the ADHD behavioral
phenotype [61].
Pretreatment for 3 days with Rg1 (10 or 30mg/kg, i.p.) or
the antibiotic minocycline (30mg/kg, i.p.) signiﬁcantly nor-
malized the BDNFmRNA levels altered by a central injection
of LPS (5μg in 5μL saline) in the cortex but not in the
hippocampus.
Rg1 administration at both low and high doses allevi-
ated the anorexic symptoms and increased the sucrose
preference [119].
The eﬀect of ginsenoside administration on naïve ani-
mals is conﬂicting. Indeed, injections of Rb1 5mg/kg/day
in 0.2 cc saline i.p. for 4 days did not modulate the BDNF
mRNA levels in the hippocampus [120], while ginsenoside
Rh1 (10mg/kg/day for 3 months) signiﬁcantly upregulated
the BDNF protein levels in the hippocampus with respect
to the control group. The Rh1-treated group (5 and 10mg/
kg) signiﬁcantly promoted the spatial learning ability in
the MWM test [121]. Finally, administration of gintonin
(50mg/kg per os, 7 days), a mixture of glycolipoproteins
from Panax ginseng, signiﬁcantly increased the BDNF pro-
tein levels [122].
Taken together, reviewed studies suggest that pure ginse-
nosides are eﬀective modulators of neuroplasticity. The main
criticism is the heterogeneity of the studies that evaluate the
eﬀect of each ginsenoside at a time.
11. Perilla frutescens (L.) Britton
Perilla frutescens (L.) Britton, also called zi-su in Chinese, is
an annual herb belonging to the Lamiaceae family; stems,
leaves, and seeds are widely used in traditional Chinese med-
icine or as food ingredients.
11.1. In Vivo Studies. Five papers investigated the eﬀect of
Perilla frutescens on in vivomodels. Administration of essen-
tial oil from commercial Perilla leaf (EOPL) for 4 weeks, at 3
or 6mg/kg, normalized the BDNF gene expression, while
only the highest dose was eﬀective at protein levels in the hip-
pocampus of chronically stressed mice. Conversely, 3 weeks
of EOPL was not enough to correct the molecular deﬁcit
observed. Moreover, EOPL produced an antidepressant-like
eﬀect in the sucrose preference test after 3 and 4 weeks at
both concentrations and in the FST at 6mg/kg after 3-week
treatment or at 3mg/kg and 6mg/kg after 4-week treatment,
while no eﬀect was observed on the locomotor activity. Inter-
estingly, a similar eﬀect was found in administering 20mg/kg
ﬂuoxetine [123].
Male mice subjected to dietary restriction of α-linolenic
acid (ALA) were fed with a diet supplemented with Perilla
oil (5%) for 8 weeks. ALA restriction lowered the BDNF
levels in the striatum, and Perilla oil signiﬁcantly increased
the BDNF protein levels [124, 125].
Six weeks of Perilla seed oil administration at 4% (w/w) in
the diet to naïve Sprague-Dawley rats signiﬁcantly upregu-
lated the concentration of BDNF in the prefrontal cortex,
while the immobility times were signiﬁcantly shorter in the
FST. A similar eﬀect was observed after i.p. injection of imip-
ramine (30mg/kg) [126].
In a recent study, chronic treatment with Perilla oil
(500mg/kg/day by gastric gavage) normalized the decrease
in BDNF protein levels in an animal model of Alzheimer’s
disease. The eﬀect paralleled the anxiolytic-like eﬀect and
improved the cognitive performance measured in both the
novel object recognition test and the MWM test [127].
On these bases, the few studies present in literature are
encouraging, but other demonstrations are mandatory to
draw clear-cut conclusions.
12. Rhodiola rosea L.
Rhodiola rosea L. (Crassulaceae) has a long history of use
as a medicinal plant in several traditional medicines. Rho-
diola root and rhizome increase the organism’s resistance
to physical, chemical, and biological stressors; the eﬀect is
mostly due to the active principle salidroside (SA, syn. rho-
dioloside) [128].
12.1. In Vitro Studies. One in vitro study evaluated the eﬀect
of SA on BDNF demonstrating that the pure compound
induced mesenchymal stem cells to diﬀerentiate into dopa-
minergic neurons. Moreover, SA treatment (100μg/mL) for
1–6 days signiﬁcantly increased the BDNF mRNA levels
while at 12 days, an opposite eﬀect was found. Diﬀerently,
the eﬀect on the BDNF protein levels was more long lasting
since it was still present after 12 days [129].
12.2. In Vivo Studies. In vivo, the treatment for 5 days (12 and
24mg/kg, per os) with SA or ﬂuoxetine prevented the devel-
opment of the depression-like behavior and of the downreg-
ulation of BDNF protein levels in the hippocampus induced
by a single injection of LPS [130].
13. Salvia miltiorrhiza Bunge
Salvia miltiorrhiza Bunge (Lamiaceae), also known as red
sage, is a perennial plant; root and rhizome are widely used
in China for the treatment of cardiovascular and cerebrovas-
cular diseases [131].
13.1. In Vitro Studies. Two in vitro studies evaluated the eﬀect
of salvianolic acid B (SalB). Treatment with SalB (20μg/mL,
for 24 h) signiﬁcantly increased the level of BDNF protein
in bone marrow-derived neural stem cells [132].
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Furthermore, SMND-309 (5, 10, and 20μM for 24h), the
metabolite produced in the brain and heart of rats after SalB
oral administration, restored the mBDNF protein expression
in the human neuroblastoma cell line SH-SY5Y subjected for
2 h to OGD/R [133].
13.2. In Vivo Studies. Salvia miltiorrhiza extracts and pure
compounds were also investigated in ﬁve in vivo studies. Hip-
pocampal BDNF immunoreactivity was markedly decreased
by the injection of the Aβ25–35 peptide in mice, and sub-
chronic treatment with SalB (10mg/kg, 7 days) reversed this
reduction [134]. A similar eﬀect was observed after oral treat-
ment for 14 days (0.81 and 0.405 g/kg) with the formulation
named Compound Danshen Tablet (CDT) (Salvia miltior-
rhiza, Panax notoginseng, and borneol in a ratio 450 : 141 : 8).
Indeed, CDT administered to mice at 0.81 g/kg or 0.405 g/kg
normalized the hippocampal BDNF mRNA levels and
improved the cognitive performance, while the lowest dose
was eﬀective also at the protein level [135].
Pretreatment with tanshinone I (10mg/kg, i.p. for 3
days), a lipophilic diterpenoid occurring in the radix of Sal-
via miltiorrhiza, administered 5 minutes before ischemia-
reperfusion by bilateral common carotid artery occlusion,
corrected the reduced BDNF immunoreactivity in the CA1
of ischemic Mongolian gerbils [136]. Similarly, salvianolic
acid A (100μg/kg) administered intravenously 2 h after
middle cerebral artery occlusion/reperfusion signiﬁcantly
reversed the protein levels of mBDNF in the ipsilateral ische-
mic brain hemisphere. Furthermore, the treatment signiﬁ-
cantly improved the reduction in tracking distance induced
by stroke injury [137].
Salvianolate lyophilized injection (10.5, 21, and 42mg/
kg) ameliorated the deﬁcits observed in diabetic rats after
stroke normalizing the protein level of the mature form of
BDNF [138].
14. Vitis vinifera L. (Red Wine)
Vitis vinifera L. is a plant belonging to the family of Vitaceae,
native to the Mediterranean region and widely used to make
wine or juice.
14.1. In Vivo Studies. Two in vivo studies were performed on
male rats. Grape powder (including that of fresh red, green,
and blue-black California grapes, seeded and seedless varie-
ties) dissolved in tap water (15 g/L) for 3 weeks attenuated
the reduction of BDNF protein levels induced by the oxida-
tive stress mediator L-buthionine-(S,R)-sulfoximine in the
amygdala, hippocampus, and cortex [139] or due to the
exposure to a single prolonged stress [140]. Moreover,
grape intake exerted an anxiolytic eﬀect and a positive
eﬀect in the memory test [139, 140]. In addition to grape
studies, few interesting papers investigated BDNF modula-
tions by red wine or ethanol starting from 60 days before
pregnancy up to pup weaning. Adult animals exposed to
only ethanol showed disrupted levels of BDNF in several
brain areas, including the hippocampus, and altered cogni-
tion and emotional behavior. Conversely, mice exposed to
red wine had no changes in the behavior but a decrease
in hippocampal BDNF [141]. Another study investigated
BDNF changes in old male mice following perinatal expo-
sure to ethanol or red wine at the same ethanol concentra-
tion. The study demonstrates that ethanol alone is able to
increase BDNF levels in limbic areas, whereas, in mice
exposed to red wine, BDNF levels were comparable to those
of control thus allowing one to hypothesize a protective
role of wine polyphenols against the damaging eﬀect of eth-
anol alone [142].
14.2. Clinical Studies.One clinical study was performed on 25
healthy fasted subjects treated with a single dose of grape seed
extract (N31, 72% polyphenols). The participants were 18–55
years old and had a body mass index between 18.0 and
25.0 kg/m2. N31 increased the BDNF levels in plasma by
30% with respect to the baseline, although the eﬀect was
not statistically signiﬁcant [53].
15. Withania somnifera (L.) Dunal
Withania somnifera (L.) Dunal, also called Ashwagandha or
Indian ginseng (Solanaceae), is a traditional Ayurvedic
remedy reputed to be useful as an antistress and memory
enhancer [143].
15.1. In Vivo Studies. Two papers investigated the eﬀect of
Withania somnifera on in vivomodels. Pretreatment with an
alcoholic extract of Ashwagandha leaves (100mg, 200mg,
and 300mg/kg for 7 days) signiﬁcantly prevented the eﬀects
due to the scopolamine treatment (3mg/kg) such as the
reduction of the mRNA expression of BDNF transcript
variant-1 and of proBDNF and mBDNF protein expression
at all the concentrations tested. On the contrary, posttreat-
ment at 200mg/kg was ineﬀective [144].
Withanolide-enriched extract from the Withania som-
nifera root (methanol–water 25 : 75, v/v) was evaluated on
induced hypobaric hypoxia in rats. Animals fed before
and after hypobaric hypoxia with 200mg/kg of the extract
showed an increased expression of BDNF and a signiﬁ-
cant decrease in latency and path length in the MWM
test [145].
16. Conclusions
In this review, we provide an upgrade of the current liter-
ature on the ability of some well-known botanicals to
modulate BDNF expression in the brain. Recently, the
strategy searching for new compounds, also from natural
sources, able to modulate neurotrophin levels, has been
increasingly explored. The growing interest in the use of
botanicals as modulators of the CNS diseases is proved
by the large amount of scientiﬁc papers we retrieved and
reviewed on this topic (more than one hundred papers
for 14 botanicals) (Figure 2). Results critically reviewed
and discussed herein emphasize how botanicals modulate
BDNF in diﬀerent pathological conditions aﬀecting the
CNS, providing an alternative strategy to the conventional
treatment. Indeed, most of the studies demonstrated that
treatment with botanicals may prevent and/or normalize
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the alterations of BDNF caused by experimental handling
(Table 2).
An added value of papers dealing with in vivo studies is
that molecular analyses parallel the investigation of an ani-
mal model’s behavior after treatment, thus allowing one to
draw clear-cut conclusions on the functional outcome associ-
ated with the correction of the molecular deﬁcits.
Indeed, despite a variety of diﬀerent pathological condi-
tions taken into consideration, from mood disorders to
Alzheimer’s disease and aging up to cerebral vascular dam-
age, the common point is the impairment of cognition.
Accordingly, among the behavioral phenotypes, the perfor-
mance in learning and memory tasks was deeply explored
as a common feature of diﬀerent diseases occurring in the
CNS and many botanicals considered have been demon-
strated to have cognitive-enhancing properties such as
Bacopa monnieri, Coﬀea arabica, Ginkgo biloba, green tea,
olive oil, Panax ginseng, Perilla frutescens, Salvia miltior-
rhiza, Vitis vinifera, and Withania somnifera.
This observation increases the meaning of the results
summarized in the present review because the positive eﬀect
on a molecular target (BDNF) and on a functional deﬁcit (in
cognition) altered in several diseases makes the therapeutic
ability of these compounds broad-spectrum.
Another point is that most studies compared the eﬀect of
botanicals with the eﬀect obtained from a reference drug,
showing similar eﬃcacy. For example, Bacopa monnieri,
Crocus sativus, Ginkgo biloba, green tea, Panax ginseng,
Perilla frutescens, and Rhodiola rosea exert antidepressant-
like eﬀects in diﬀerent behavioral tests compared to the clas-
sical drugs used in therapy. However, most of the clinical
studies reported in the present review do not pay attention
to the side eﬀects following botanical treatment.
Moreover, even if promising results have been found on
Crocus sativus, Eleutherococcus senticosus Maxim., Hyperi-
cum perforatum, Rhodiola rosea, Salvia miltiorrhiza Bunge,
Vitis vinifera, and Withania somnifera Dunal and BDNF
modulation, the number of studies of these botanicals is too
low for drawing conclusive results.
The current revision of the literature suggests that
several issues need to be considered to draw consistent con-
clusions. Firstly, considering the complexity of the BDNF
system, as brieﬂy described in the introduction, a more
reﬁned analysis of the diﬀerent elements both at transcrip-
tion and translational levels is mandatory. Indeed, very
few studies report the BDNF isoform or the form measured,
and, in some cases, the molecular weight of the band exam-
ined does not correspond to either the mature or the pre-
cursor form.
Secondly, though not negligible, the number of clinical
studies is very limited since few clinical trials have been
found in literature. Among them, the ﬁrst was carried out
in schizophrenic patients following treatment with Ginkgo
biloba L. extract [68] and the second was performed in
depressed patients treated with Hypericum perforatum L.
[84], whereas the others were performed in healthy subjects.
Although the eﬀect obtained from those studies was relevant,
the paucity of clinical trials implies that botanicals discussed
in the present review need to be carefully considered for
human studies.
Standardization of the extract is an important prerequi-
site for eﬃcacy of botanicals. Knowledge of the active princi-
ples is the ﬁrst step for an adequate standardization. Results
reported in literature show that ginsenosides are mostly
responsible for BDNF modulation exerted by Panax ginseng
C.A. Meyer whereas rhodioloside appears to be the main
active principle occurring in Rhodiola rosea L. However, for
other botanicals, the molecules driving the pharmacological
eﬀects are not clearly deﬁned (i.e., Vitis vinifera L. or olive
oil (Olea europaea L.)) and only speculations can be done
at this regard. Thus, it is important to underline that most
of the studies reviewed herein used standardized extracts,
Botanicals
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Number of studies
Panax ginseng C.A. Meyer
Coffea arabica  L.
Camellia sinensis  (L.) Kuntze (green tea)
Bacopa monnieri (L.) Pennell
Ginkgo biloba  L.
Salvia miltiorrhiza  Bunge
Olea europaea L. (olive oil)
Perilla frutescens (L.) Britton
Vitis vinifera  L.
Hypericum perforatum  L.
Crocus sativus L.
Rhodiola rosea L.
Withania somnifera  (L.) Dunal
Eleutherococcus senticosus
(Rupr. & Maxim.) Maxim.
Figure 2: Number of studies investigating BDNF in the central nervous system for each botanical or active principle.
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Table 2: Summary of the experimental conditions employed to investigate the eﬀect of botanical administration on BDNF expression.
Botanicals Type of studies Models mRNA Protein References
Bacopa monnieri (L.)
In vitro PC12 • [23, 24]
In vivo
Naïve animals • • [32]
Chronic stress • • [25, 27]
• [26]
Fear conditioning • [33]
Olfactory bulbectomy • [29]
Scopolamine • [30]
• • [31]
Coﬀea arabica L.
In vitro
Hippocampal neurons • [34, 35]
Cortical neurons • [36]
In vivo
Naïve animals • [38–43]
• [37]
Alzheimer’s disease • [44]
• [45]
Chronic stress • [46]
Obesity (high-fat diet) • [47]
Sleep deprivation • [49]
• [50–52]
Clinical Healthy subjects • [53]
Crocus sativus L. In vivo Naïve animals • • [55, 56]
Eleutherococcus senticosus
(Rupr. & Maxim.) Maxim.
In vitro PC12 • [58]
Ginkgo biloba L.
In vitro
N2a • [59]
(APP/PS1) primary neurons • [60]
SH-SY5Y • [61]
In vivo
Naïve animals • [63, 67]
Alzheimer’s disease • [60]
ADHD • [61]
Cerebral ischemia-reperfusion • [62]
Chronic stress • [66]
Haloperidol • [65]
LPS-induced depression • [64]
Clinical Tardive dyskinesia patients • [68]
Green tea
(Camellia sinensis (L.) Kuntze)
In vitro
SH-SY5Y • [70]
Cortical cultures • [71]
In vivo
Naïve animals • [72–76]
• [77]
Alzheimer’s disease • [79, 80]
DYRK1A transgenic mice • [78]
Obesity (high-fat diet) • [81]
Hypericum perforatum L.
In vivo Chronic stress • [82, 83]
Clinical Depressed patient • [84]
Olive oil (Olea europaea L.)
In vivo
Naïve animals • [87, 88]
• [89]
Alzheimer’s disease • [91]
Prenatal stress • [90]
Clinical
Healthy subjects • [92]
Alcoholic patients • [93]
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although few papers did not report properly the type of sol-
vent used.
In conclusion, considering the key role of the marker
in diﬀerent pathological conditions aﬀecting the CNS, BDNF
may represent an important tool to counteract these
conditions, as demonstrated by the studies reported herein.
Botanicals may be considered useful candidates to modulate
in vivo BDNF. If clinical studies conﬁrm this evidence, these
natural products may be used for preventing CNS dysfunc-
tion or as a useful adjuvant to the pharmacological treatment.
Table 2: Continued.
Botanicals Type of studies Models mRNA Protein References
Panax ginseng C.A. Meyer
In vitro
OECs • • [94]
PC12 • [98]
Rat brain slices • [96]
Rat hippocampal neurons • [97]
SCs • • [95]
In vivo
Naïve animals • [114, 121, 122]
• [120]
Acute stress • • [108]
• [104]
Alzheimer’s disease • [115]
ADHD • [61]
Autoimmune encephalomyelitis • [112]
Cerebral ischemia-reperfusion • [116, 117]
• • [118]
Chronic stress • [99, 101–103, 107]
• [106]
• • [100]
Corticosterone • • [105]
LPS-induced depression • [119]
Scopolamine • [110]
• [109]
SAMP8 • [113]
Streptozotocin • [111]
Perilla frutescens (L.) Britton In vivo
Alzheimer’s disease • [127]
Chronic stress • • [123]
Dietary restriction of ALA • [124, 125]
Naïve animals • [126]
Rhodiola rosea L.
In vitro Mesenchymal stem cells • • [129]
In vivo LPS-induced depression • [130]
Salvia miltiorrhiza Bunge
In vitro
BM-NSCs • [132]
SH-SY5Y • [133]
In vivo
Alzheimer’s disease • [134]
• • [135]
Cerebral ischemia-reperfusion • [136, 137]
Streptozotocin and cerebral ischemia-reperfusion • [138]
Vitis vinifera L.
In vivo
Naïve animals • [141, 142]
Acute stress • [140]
Oxidative stress • [139]
Clinical Healthy subjects • [53]
Withania somnifera (L.) Dunal In vivo
Hypobaric hypoxia • [145]
Scopolamine • • [144]
Studies which measured the BDNF mRNA or protein levels are indicated with the symbol “•”.
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